Table 3.
Odds ratios and 95% confidence intervals of detectable HIV RNA, percentage covered time and longest interruption in treatment, by medication regimen type.
| Modela | NNRTI (n = 547) | Boosted-PI (n = 315) | PI (n = 1919) | Other (n = 1014) | Total (n = 3795) |
|---|---|---|---|---|---|
| Covered time | |||||
| 93–100% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 76–92% | 1.01 (0.60, 1.64) | 0.83 (0.46, 1.52) | 1.00 (0.73, 1.36) | 1.21 (0.76, 1.92) | 1.03 (0.83, 1.28) |
| 51–75% | 1.11 (0.61, 2.00) | 0.63 (0.31, 1.26) | 1.22 (0.87, 1.73) | 1.13 (0.63, 2.00) | 1.11 (0.86, 1.42) |
| 26–50% | 2.43 (1.31, 4.53) | 1.04 (0.46, 2.34) | 1.74 (1.18, 2.57) | 1.57 (0.86, 2.87) | 1.68 (1.28, 2.22) |
| 0–25% | 4.08 (2.09, 8.22) | 2.77 (1.27, 6.00) | 3.06 (2.07, 4.52) | 3.36 (2.03, 5.54) | 3.22 (2.48, 4.19) |
| Length of longest interruptionb | |||||
| <48 h | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| >2 ≤ 7 days | 1.12 (0.61, 1.52) | 1.24 (0.73, 2.09) | 1.35 (1.06, 1.73) | 0.89 (0.59, 1.35) | 1.15 (0.96, 1.40) |
| >7 ≤ 14 days | 1.91 (1.10, 3.33) | 2.46 (1.36, 4.45) | 2.16 (1.50, 3.11) | 1.92 (1.13, 3.24) | 2.06 (1.58, 2.68) |
| >14 ≤ 21 days | 3.37 (1.75, 6.50) | 4.38 (1.57, 12.2) | 2.65 (1.72, 4.09) | 2.29 (1.29, 4.08) | 2.74 (2.04, 3.67) |
| >21 ≤ 28 days | 4.38 (2.17, 8.81) | 3.43 (1.49, 7.91) | 3.21 (2.20, 4.68) | 4.21 (2.60, 6.85) | 3.65 (2.77, 4.81) |
NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor. All interaction terms were P > 0.05.
a
All models were estimated using generalized estimating equations with robust standard errors and a fixed effect for study site.
b
Longest interruption models were also adjusted for remaining noncovered time from the prior 28 days.